Analysts at Berenberg have reiterated a 'Buy' rating on Greatland Gold PLC (AIM:GGP, OTC:GRLGF) following recent key funding and board strengthening news plus its plans to list on the Australian Stock Exchange (ASX)
The Berenberg analysts, however, cut their share price target for Greatland Gold to 18.00p from 22.00p to reflect higher dilution than previously expected. In late afternoon trade on Tuesday, Greatland shares were trading at 9.05p, up 0.3% on Monday's close having jumped higher that session when the news was announced.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) said it has presented a new poster at the 100th American Society for Clinical Pathology (ASCP) meeting in Chicago.
The poster, which describes the novel use of Papanicolaou (Pap) staining procedures with cells harvested from blood samples using ANGLE's Parsortix biopsy system, was selected as a finalist for a prestigious Blue Ribbon award for laboratory practice by ASCP judges.
Futura Medical PLC (AIM:FUM, OTC:FAMDF) looks financially well set for the commercial phase of the journey of its lead product, MED3000 for erectile dysfunction.
Interim results for the group showed it had £6.68mln in the bank as of June 30, 2022, the period's end, with a further £910,000 in research and development tax credits set for payment in the second half.
Accesso Technology Group PLC (AIM:ACSO, OTC:LOQPF) posted growth in revenue and profitability well ahead of pre-pandemic levels in the first half as visitors returned to theme parks and other attractions.
The technology provider said it expects the full-year 2022 to be in line with board expectations at the start of the year, excluding costs associated with a US$0.75mln acquisition of technology assets in the food & retail space.
Bradda Head Lithium Ltd said it has completed the first hole of its current 30-hole San Domingo pegmatite exploration programme in Central Arizona.
The company has confirmed significant intersections of spodumene-bearing pegmatite in this first hole.
Faron Pharmaceuticals Oy (AIM:FARN, OTC:FPHAF) said its Traumakine drug has shown early promise as a potential therapeutic for emergency and trauma patients, especially when given early on.
The company said primates were treated intravenously with interferon beta-1a formulation at the time of major inflammation due to ischemia (where blood flow and oxygen are restricted to a part of the body).